Camber Pharmaceuticals releases Spironolactone Oral Suspension to its portfolio. As an antagonist of aldosterone, it is indicated for the treatment of NYHA Class III to IV heart failure with reduced ejection fraction to improve survival, manage edema, and reduce hospitalizations, as well as for managing edema in adult cirrhotic patients who are unresponsive to fluid and sodium restriction. It can also be used as an add-on therapy for hypertension to lower blood pressure and reduce the risk of cardiovascular events, including strokes and myocardial infarctions. Spironolactone Oral Suspension is available in 25 mg/5 mL strength and comes in 118 mL and 473 mL bottle sizes. Complete indications and more information can be found online.